Table 4.
The comparison of average revenue earned per employee across different pharmaceutical companies
| Company | Type | Founded | Number of employees | Average 10 years (2006–2016) revenue (M$) | Revenue per employee ($) |
|---|---|---|---|---|---|
| Helsinn | NRDO | 1976 | 680 | 320 | 470,588 |
| Jazz Pharma | NRDO | 2003 | 1040 | 615 | 591,346 |
| Tesaro+ | NRDO | 2010 | 446 | 0.45 | 1010 |
| Puma Biotech++ | NRDO | 2010 | 183 | 0 | 0 |
| Clovis | NRDO | 2009 | 278 | 0.14 | 504 |
| Vanda Pharma | NRDO | 2002 | 148 | 38 | 256,756 |
| Debiopharm | NRDO | 1979 | 150 | 345 | 2,300,000 |
| Astra Zeneca | Large Pharma | 1999 | 59,700 | 23,000 | 385,260 |
| Novartis | Large Pharma | 1996 | 12,3000 | 47,000 | 382,114 |
| Sanofi | Large Pharma | 2004 | 110,000 | 32,500 | 295,454 |
| Eli Lilly | Large Pharma | 1876 | 42,000 | 21,500 | 511,905 |
| Bayer | Large Pharma | 1863 | 115,000 | 43,000 | 373,913 |
| Pfizer | Large Pharma | 1849 | 96,500 | 51,000 | 528,497 |
| GSK | Large Pharma | 2000 | 99,300 | 26,400 | 345,619 |
| Amgen | Large Biotech | 1980 | 19,200 | 20,000 | 1,041,667 |
NRDO ‘No Research, Development Only’ companies that do not conduct early research and have not chosen to conduct sell and market their own assets; + calculated over 6 years; ++ calculated over 7 years